Nicholas A. Smith

Array ( [id] => 10063908 [patent_doc_number] => 09102739 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-08-11 [patent_title] => 'Anti-glypican-3 antibody' [patent_app_type] => utility [patent_app_number] => 12/089957 [patent_app_country] => US [patent_app_date] => 2006-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 9968 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12089957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5022205 [patent_doc_number] => 20070148171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-06-28 [patent_title] => 'Optimized anti-CD30 antibodies' [patent_app_type] => utility [patent_app_number] => 11/544165 [patent_app_country] => US [patent_app_date] => 2006-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 44131 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0148/20070148171.pdf [firstpage_image] =>[orig_patent_app_number] => 11544165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5085409 [patent_doc_number] => 20070275460 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-11-29 [patent_title] => 'Fc Variants With Optimized Fc Receptor Binding Properties' [patent_app_type] => utility [patent_app_number] => 11/538411 [patent_app_country] => US [patent_app_date] => 2006-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 29410 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0275/20070275460.pdf [firstpage_image] =>[orig_patent_app_number] => 11538411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5022204 [patent_doc_number] => 20070148170 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-06-28 [patent_title] => 'Fc Variants With Optimized Fc Receptor Binding Properties' [patent_app_type] => utility [patent_app_number] => 11/538406 [patent_app_country] => US [patent_app_date] => 2006-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 29259 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0148/20070148170.pdf [firstpage_image] =>[orig_patent_app_number] => 11538406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5241768 [patent_doc_number] => 20070020260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-01-25 [patent_title] => 'GLYCOPROTEIN COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 11/536186 [patent_app_country] => US [patent_app_date] => 2006-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 41385 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0020/20070020260.pdf [firstpage_image] =>[orig_patent_app_number] => 11536186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7688629 [patent_doc_number] => 20070106069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-05-10 [patent_title] => 'Non-Human Primate Fc Receptors and Methods of Use' [patent_app_type] => utility [patent_app_number] => 11/535824 [patent_app_country] => US [patent_app_date] => 2006-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 26982 [patent_no_of_claims] => 64 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0106/20070106069.pdf [firstpage_image] =>[orig_patent_app_number] => 11535824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6070141 [patent_doc_number] => 20110044991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-02-24 [patent_title] => 'METHODS AND COMPOSITIONS FOR TREATING LYMPHOMA AND MYELOMA' [patent_app_type] => utility [patent_app_number] => 12/439878 [patent_app_country] => US [patent_app_date] => 2006-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 12137 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0044/20110044991.pdf [firstpage_image] =>[orig_patent_app_number] => 12439878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6615351 [patent_doc_number] => 20100323905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-12-23 [patent_title] => 'Vhh for the Diagnosis, Prevention and Treatment of Diseases Associated with Protein Aggregates' [patent_app_type] => utility [patent_app_number] => 11/992330 [patent_app_country] => US [patent_app_date] => 2006-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 31635 [patent_no_of_claims] => 57 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0323/20100323905.pdf [firstpage_image] =>[orig_patent_app_number] => 11992330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4994178 [patent_doc_number] => 20070009523 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-01-11 [patent_title] => 'Polypeptide variants with altered effector function' [patent_app_type] => utility [patent_app_number] => 11/520121 [patent_app_country] => US [patent_app_date] => 2006-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 48868 [patent_no_of_claims] => 79 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0009/20070009523.pdf [firstpage_image] =>[orig_patent_app_number] => 11520121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4994178 [patent_doc_number] => 20070009523 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-01-11 [patent_title] => 'Polypeptide variants with altered effector function' [patent_app_type] => utility [patent_app_number] => 11/520121 [patent_app_country] => US [patent_app_date] => 2006-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 48868 [patent_no_of_claims] => 79 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0009/20070009523.pdf [firstpage_image] =>[orig_patent_app_number] => 11520121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 295762 [patent_doc_number] => 07541029 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2009-06-02 [patent_title] => 'Anti-rhesus D monoclonal antibodies' [patent_app_type] => utility [patent_app_number] => 11/517525 [patent_app_country] => US [patent_app_date] => 2006-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 13 [patent_no_of_words] => 11615 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/541/07541029.pdf [firstpage_image] =>[orig_patent_app_number] => 11517525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5514222 [patent_doc_number] => 20090214528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-08-27 [patent_title] => 'HOST CELL LINES FOR PRODUCTION OF ANTIBODY CONSTANT REGION WITH ENHANCED EFFECTOR FUNCTION' [patent_app_type] => utility [patent_app_number] => 12/065178 [patent_app_country] => US [patent_app_date] => 2006-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 13989 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0214/20090214528.pdf [firstpage_image] =>[orig_patent_app_number] => 12065178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8283052 [patent_doc_number] => 08217147 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-07-10 [patent_title] => 'Identification and engineering of antibodies with variant Fc regions and methods of using same' [patent_app_type] => utility [patent_app_number] => 11/502820 [patent_app_country] => US [patent_app_date] => 2006-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 69 [patent_figures_cnt] => 107 [patent_no_of_words] => 100189 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 11502820 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5182555 [patent_doc_number] => 20070053901 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-03-08 [patent_title] => 'Optimized Fc variants and methods for their generation' [patent_app_type] => utility [patent_app_number] => 11/495242 [patent_app_country] => US [patent_app_date] => 2006-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 84379 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0053/20070053901.pdf [firstpage_image] =>[orig_patent_app_number] => 11495242 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5056384 [patent_doc_number] => 20070059306 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-03-15 [patent_title] => 'B-cell reduction using CD37-specific and CD20-specific binding molecules' [patent_app_type] => utility [patent_app_number] => 11/493132 [patent_app_country] => US [patent_app_date] => 2006-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 39 [patent_no_of_words] => 31526 [patent_no_of_claims] => 117 [patent_no_of_ind_claims] => 22 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0059/20070059306.pdf [firstpage_image] =>[orig_patent_app_number] => 11493132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6536271 [patent_doc_number] => 20100015644 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-01-21 [patent_title] => 'Potency assays for antibody drug substance binding to an fc receptor' [patent_app_type] => utility [patent_app_number] => 11/989064 [patent_app_country] => US [patent_app_date] => 2006-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 28651 [patent_no_of_claims] => 161 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0015/20100015644.pdf [firstpage_image] =>[orig_patent_app_number] => 11989064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5153903 [patent_doc_number] => 20070036786 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-02-15 [patent_title] => 'Method of treating autoimmune disease using humanized anti-CD16A antibodies' [patent_app_type] => utility [patent_app_number] => 11/485556 [patent_app_country] => US [patent_app_date] => 2006-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 34211 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0036/20070036786.pdf [firstpage_image] =>[orig_patent_app_number] => 11485556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9344489 [patent_doc_number] => 08663634 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-03-04 [patent_title] => 'Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity' [patent_app_type] => utility [patent_app_number] => 11/485557 [patent_app_country] => US [patent_app_date] => 2006-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 48933 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 11485557 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5079182 [patent_doc_number] => 20070122406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-05-31 [patent_title] => 'Optimized proteins that target Ep-CAM' [patent_app_type] => utility [patent_app_number] => 11/484198 [patent_app_country] => US [patent_app_date] => 2006-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 44800 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0122/20070122406.pdf [firstpage_image] =>[orig_patent_app_number] => 11484198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 278114 [patent_doc_number] => 07557190 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2009-07-07 [patent_title] => 'Optimized proteins that target Ep-CAM' [patent_app_type] => utility [patent_app_number] => 11/484183 [patent_app_country] => US [patent_app_date] => 2006-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 33 [patent_no_of_words] => 45013 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 244 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/557/07557190.pdf [firstpage_image] =>[orig_patent_app_number] => 11484183 [rel_patent_id] =>[rel_patent_doc_number] =>)